Rational Pharmacotherapy in Cardiology

Advanced search


Full Text:


The problem of varenicline use in patients with cardiovascular diseases is discussed. Results of large clinical trials and meta-analyses with varenicline have proven its high efficacy for treatment of nicotine addiction in adults and a small number of side events. Varenicline is the main agent for pharmacotherapy of nicotine addiction due to its high efficacy and advantages of smoking cessation. However careful monitoring of its side effects is needed in these patients.

About the Authors

Yu. V. Lukina
State Research Center for Preventive Medicine, Moscow
Russian Federation

S. Yu. Martsevich
State Research Center for Preventive Medicine, I.M. Sechenov First Moscow State Medical University, Moscow
Russian Federation


1. World Health Organization Tobacco Free Initiative. The tobacco industry's war on public health: tobacco kills – don't be duped. Available at: Date of access: 30.07.2013.

2. Tobacco Could Kill One Billion By 2100, WHO Report Warns Science Daily. Available at: http://www.sci- Date of access: 30.07.2013.

3. WHO Framework Convention on Tobacco Control. Available at: load/ru/index.html. Date of access: 30.07.2013.

4. MPOWER: a policy package to reverse the tobacco epidemic. World Health Organization, 2008. Available at: htpp:// Date of access: 30.07.2013.

5. International Statistical Classification of Diseases and Related Health Problems 10th Revision. Available at: Date of access: 30.07.2013.

6. Fagerstrom Test for Nicotine Dependence. Available at: ments/Fagerstrom_test.pdf. Date of access: 30.07.2013.

7. U.S. Food and Drug Administration. FDA Approves Novel Medication for Smoking Cessation. Press release. 11 May 2006. Available at ments/2006/ucm108651.htm. Date of access: 30.07.2013.

8. The state register of medical products. Available at:варениклин. Date of access: 30.07.2013. Государственный реестр лекарственных средств. Доступно на:варениклин. Дата доступа: 30.07.2013.

9. Mihalak K., Carroll F., Luetje C. Varenicline is a partial agonist at α4β2 and a full agonist at α7 neuronal nicotinic receptors. Mol Pharmacol 2006; 70: 801-805.

10. Foulds J. The neurobiological basis for partial agonist treatment of nicotine dependence: Varenicline. Int J Clin Pract 2006; 60: 571-576

11. Fant RV, Buchhalter AR, Buchman AC, Henningfield JE. Pharmacotherapy for tobacco dependence. Handb Exp Pharmacol 2009;(192):487-510

12. Aubin H., Bobak A., Britton J.R. et al. Varenicline versus transdermal nicotine patch for smoking cessation: results from a randomised, open-label trial. Thorax 2008; (1): 1-8.

13. Gonzales D., Rennard S., Nides M. et al. Varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation. JAMA 2006; 296 (1): 47-55.

14. Jorenby D., Hays J., Rigotti N. Efficacy of Varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation. JAMA 2006; 296 (1): 56-63

15. FDA Drug Safety Communication: Chantix (varenicline) may increase the risk of certain cardiovascular adverse events in patients with cardiovascular disease. Available on: Date of access: 30.07.2013.

16. Singh S, Loke YK, Spangler JG, Furberg CD. Risk of serious adverse cardiovascular events associated with varenicline: a systematic review and meta-analysis. CMAJ 2011;183:1359-66

17. Hays JT. Varenicline for smoking cessation: is it a heartbreaker? CMAJ 2011;183:1346-7

18. Rigotti NA, Pipe AL, Benowitz NL, et al. Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease: a randomized trial. Circulation 2010;121:221-9.

19. European Medicines Agency confirms positive benefit-risk balance for Champix. Available on: c1&jsenabled=true. Date of access: 30.07.2013.

20. FDA Drug Safety Communication: Safety review update of Chantix (varenicline) and risk of cardiovascular adverse events. Available on: Date of access: 30.07.2013.

21. Svanström H, Pasternak B, Hviid A. Use of varenicline for smoking cessation and risk of serious cardiovascular events: nationwide cohort study. BMJ 2012;345:e7176

22. Prochaska JJ, Hilton JF. Risk of cardiovascular serious adverse events associated with varenicline use for tobacco cessation: systematic review and meta-analysis. BMJ 2012; 344:e2856.


For citation:

Lukina Yu.V., Martsevich S.Yu. VARENICLINE IN PATIENTS WITH CARDIOVASCULAR DISEASES – FRIEND OR ENEMY? Rational Pharmacotherapy in Cardiology. 2013;9(4):455-458. (In Russ.)

Views: 566

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.

ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)